About The Author

I am currently a Ph.D. candidate at UIUC working in Prof. Hergenrother's laboratory. My research utilizes synthetic chemistry to discover transformative anticancer approaches that push the boundaries of our basic understanding of cancer, as well as translate these discoveries into direct and actionable solutions in the clinic. My expertise is highly multidisciplinary with experience in small molecule synthesis, chemical biology, cancer biology, in vivo models, veterinary oncology, intellectual property, technology licensing, clinical development, and clinical trial design.

Combating Resistance To Targeted Anticancer Therapies Via Caspase-3-Mediated MEK Degradation

Matthew W. Boudreau & Paul J. Hergenrother |  

Increasingly, anticancer drugs targeting mutant or fusion proteins found in a patient’s tumor are becoming the gold standard for modern-day cancer treatment. This personalized approach to oncology has led to dramatic results in the clinic, with potent tumor reduction being observed in a variety of disease traditionally considered recalcitrant to treatment. While these drugs often

Read more →